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A B S T R A C T
Objectives
This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the comparative eOectiveness and safety of interventions used in the management of alopecia areata (AA), including patchy
alopecia (PA), alopecia totalis (AT) and alopecia universalis (AU).
To establish rankings of the available treatments for AA, based on their eOectiveness and safety (primary outcomes), through a network
meta-analysis.
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B A C K G R O U N D
A glossary of terms is provided in Table 1.
Description of the condition
Alopecia areata (AA) is a common, inflammatory, nonscarring
type of hair loss, characterized by small patches of hair loss on
the scalp or around the body, as well as periods of relapse or
remission, aOecting the quality of life of both patients and their
caregivers (Hunt 2005; Villasante 2015). AA primarily aOects the
scalp; however, it also can aOect nails, eyelashes, eyebrows, and
other hair follicles in the patient's body (Strazzulla 2018b).
Involvement of the nails occurs in 10% to 66% of all cases of AA
and is present in 15.4% of AA universalis cases; it is more frequent
in severe forms of AA. Deterioration of the nails can be observed
before hair loss and can persist aSer treatment and hair regrowth; it
may indicate severity of AA and disease that does not get better with
treatment (refractory disease) (Ferreira 2016). The clinical signs are
nail dystrophy (change in nail shape), brittleness, fragility, pitting
and trachyonychia (damaged or broken nails).
There are three types of alopecia areata, defined according to the
aOected area: a) patchy alopecia (PA), as seen in 90% of clinical
diagnoses; b) alopecia totalis (AT), that aOects all scalp hairs; and
c) alopecia universalis (AU), involving all scalp and body hairs
(Islam 2015). The cause of AA is still being researched, but currently
genetics and immune function seem to be the most relevant
contributors to disease. Recently, some studies have suggested that
the destruction of the hair follicle generated by an immune disorder
could play a role in the appearance of AA (Juarez-Rendon 2017;
Paus 2018; Pratt 2017; Strazzulla 2018b).
The lifetime incidence reported for the US population ranges
between 1.7% and 2.1%, and the prevalence varies between
populations and studies, ranging from 0.1% to 0.2% in the general
population (Mirzoyev 2014; Safavi 1992; Safavi 1995). The pooled
prevalence estimates are 0.08% for AT and 0.03% for AU, and the
overall incidence proportion is 3.37% for AT and 0.02% for AU (Lee
2019). There are no clear diOerences by race or gender, however
almost 20% of patients have a family history of AA. Of all cases with
AA, 20% occur in childhood. The prevalence of AA in children and
adolescents is 1.83%, and between 10% and 51.6% of those with
AA have a family history of the condition. 40.2% present their first
episode of AA at 20 years old (Lee 2019; Korta 2018; Pratt 2017).
The extent of hair loss is considered the most important prognostic
factor; those with greater hair loss respond less to treatment, and
have a greater likelihood of progressing to chronic disease. Other
factors related to less favourable prognosis are early age, atopic
dermatitis, autoimmune diseases, and nail changes (Lee 2017).
There is a strong association between AA and other autoimmune
diseases; thyroid disorders are the most common accompanying
conditions, with a prevalence of 19% (Islam 2015). Other diseases
commonly associated with AA include: lupus erythematous, atopic
dermatitis, and psychiatric diseases (Conic 2017; Lee 2019).
The psychological and social eOects of AA impact substantially on
patients' health-related quality of life. Compared with the general
population, people with AA have increased risk in three out of
the four mental health domains of the SF-36 physical and mental
health summary scales ("role-emotional, mental health, vitality")
(Rencz 2016). Psychiatric disorders can trigger the onset of AA
and the role of psychological stress in people with AA may be
related to psychiatric comorbidities including anxiety, depression,
social phobia, and personality disorders. Young male patients are
at greater risk for psychological distress and suicide, and require
careful monitoring (Rencz 2016).
The diagnosis of AA is based on typical clinical presentation (acute
alopecia in well-circumscribed patches of normal-appearing skin)
(Gilhar 2012). The 'pull test' (pulling diOerent sections of the hair
to assess the severity of hair loss) is useful to evaluate the activity
of the disease. Trichoscopy (a method of magnification to assess
the hair and scalp) may be useful to confirm the diagnosis and
for uncertain cases. The main trichoscopic features of AA are:
'exclamation mark' hairs, yellow dots, black dots, broken hairs and
coudability hairs (Strazzulla 2018b). Biopsy should be performed
in unclear cases. Acute AA has the following histopathological
features: peribulbar lymphocytic infiltrate (known as 'swarm of
bees'), dilated follicular infundibula (known as 'swiss cheese
pattern'), and increased percentage of telogen hairs (a resting
phase where hair is shed) (Gordon 2011). In patients with chronic
disease, this pattern may be absent (Gilhar 2012; Strazzulla 2018b).
In the natural history of the disease, hair regrowth occurs in 34%
to 50% of patients within one year, and 15% to 25% will progress
to AT. The long-term prognosis is directly associated with the
severity of AA (Bernardis 2018; Hammerschmidt 2014). It has been
a challenge for researchers and clinicians to quantify AA in real
time. The Severity of Alopecia Tool Scoring (SALT) is a quantitative,
reproducible, standardized and simple system that allows a clinical
assessment of the amount of terminal hair loss in four views, and
can be used to track treatment response (Olsen 2004; Strazzulla
2018b).
Description of the intervention
Most cases of AA remit spontaneously, and it may be appropriate
not to medically treat if this is consistent with the patient’s
wishes; however, remission is not common in severe AA. A
considerable number of patients require medical management to
improve the growth of their hair; such management is mainly
focused on stopping the local immune response against the
hair follicle. There are diOerent types of interventions currently
in use, including local and systemic corticosteroids, contact
immunotherapy, topical immune suppressants, biological agents,
laser treatment, psychological support, and cosmetic strategies
(Lee 2017; Murad 2018; Pratt 2017).
Immunosuppressant therapy
Normally in the paediatric population, the treatment used as
the first option is topical corticosteroids of class I and II, since
they have minimal adverse eOects and are easily applied in
their diOerent presentations (lotion, foam, or shampoo). Adverse
events that may occur due to chronic use must be taken into
account (Peloquin 2017). Intralesional corticosteroids are among
the first-line alternatives in patients older than 12 years old
with patchy AA (Lee 2017; Pratt 2017). Usually, triamcinolone
acetonide is administered by injection with a fine needle into
the superior subcutaneous tissue, with the aim of stimulating
hair growth at the site of injection (Kassim 2014). Most patients
need multiple injections (Pratt 2017). Oral corticosteroids (e.g.
oral prednisolone, prednisone, and dexamethasone) have been
Treatments for alopecia areata: a network meta-analysis (Protocol)
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used successfully for extensive and rapidly progressive AA (e.g. an
extension larger than 50% of the scalp). As some patients would
need a prolonged treatment to maintain hair growth, the benefits
of this management should be balanced against the adverse eOects
(e.g. cutaneous atrophy, Cushing's syndrome) (Pratt 2017).
Systemic cyclosporine, methotrexate and azathioprine could be
used as an isolated treatment or as an adjuvant therapy to reduce
the use of systemic corticosteroids. They have potential adverse
eOects (e.g. hepatotoxicity, renal failure, higher risk of infections),
so a careful study of benefit-risk balance should be performed in
each case (Pratt 2017).
There are other therapeutic options considered to be
immunosuppressant, mostly used in combination with first-
line agents: topical calcineurin inhibitors (Price 2005), and
phototherapy with psoralens-(PUVA) (Whitmont 2003).
Anti-TNF biological agents
TNF alpha is an inflammatory cytokine that has been implicated
in AA, and anti-TNF biologic agents (etanercept, adalimumab,
infliximab, among others) are drugs that inhibit the physiological
response to this pro-inflammatory cytokine and help stop
inflammation. These drugs are not the first choice for the treatment
of AA, as there is scarce evidence of their eOicacy (Alsantali 2011).
Other biological agents
Other new biological agents (e.g. alefacept, tofacitinib, ruxolitinib,
baracitinib), have been recently proposed as potentially useful for
severe forms of AA. Among them, the most promising alternative
are the Janus kinases (JAK) inhibitors (Hosking 2018; Kostovic 2017;
Liu 2018; Strazzulla 2018a).
Topical immunotherapy (contact immunotherapy)
Contact immunotherapy is the first line of management for
patients with more than 50% of hair loss of the scalp (Perera
2015; Sutherland 2015; Yoshimasu 2016). This intervention
starts with an induced contact dermatitis through topical
administration of a chemical sensitizer (e.g. dinitrochlorobenzene-
DNCB, diphencyprone-DPCP, squaric acid dibutyl ester-SADBE,
or anthralin-dithranol) (Jang 2017). The local contact dermatitis
induces a change in the lymphocytes as well as a Th2 response (the
eOect is due to irritancy not allergy). Related adverse events include
local (e.g. pruritus, blistering, exudate) and distant reactions (e.g.
disseminated eczema, urticaria). Contact immunotherapy is free of
systemic adverse eOects and it can be maintained over a long-term
period.
Hair growth stimulants
Minoxidil has been evaluated in several studies of AA in both adults
and children, and its eOicacy is related to a sustained hair growth
eOect. In general, it is used in combination with other treatments
(i.e. topical or intralesional steroids) (Fiedler-Weiss 1987; Maitland
1984; Price 1987).
Other therapies
Additional therapeutic options (mostly used in combination with
first-line agents) include laser therapy, cryotherapy, and vitamins
(Gupta 2017; Strazzulla 2018a).
How the intervention might work
Pathogenesis of AA is related to several factors, including
autoimmunity in combination to a genetic contribution (Spano
2015). In selected cases with limited patchy hair loss, spontaneous
resolution occurs within the first year in 34% to 50% of cases.
However, extensive areas of AA have a poor prognosis (Tosti 2006).
Currently, there is no cure for AA, although there are many possible
treatments focusing on the degree of hair loss and the patient's
preferences.
Immunosuppressant therapy
The mechanism of action of corticosteroids involves the reduction
of CD3+ T cells, CD8+ T cells, CD11c+ dendritic cells and CD1a
+ Langerhans cells. In addition, it has been reported that
corticosteroid treatment causes a downregulation eOect over genes
that encode several interleukins and chemokines (proteins and
molecular messengers) (IL12B, CC-chemokine ligand 18, and IL32),
as well as upregulation of genes encoding several keratins (KRT35,
KRT75, and KRT86) (Fuentes-Duculan 2016; Kurosawa 2006).
Although the mechanism of action of methotrexate in the
management of AA is not completely known, the evidence
suggests that it produces an inhibition of the enzyme dihydrofolate
reductase, then causing an increase in adenosine and release
into the extracellular space, which inhibits the accumulation of
white blood cells, as well as a variety of activities of monocytes,
macrophages and T cells, but it also leads to a reduction in
synthesis of TNF-α and interferon gamma (Hammerschmidt 2014).
Cyclosporine has an immunosuppressive eOect (suspends the
immune response), which allows it to block gene transcription in
activated T cells that codify for diOerent cytokines. It also regulates
nuclear translocation and activation of NFAT (nuclear factor of
activated T-cells) due to the inhibition of the phosphatase activity
of calcineurin (Matsuda 2000).
Azathioprine inhibits the synthesis of DNA and decreases the
proliferation of T and B lymphocytes. In addition, it decreases the
number of Langerhans cells and other antigen-presenting cells of
the skin (Farshi 2010).
Anti-TNF biological agents
Recent studies on AA development suggest the involvement of the
tumour necrosis factor-alpha (TNF-alpha); hence, some biological
drugs such as adalimumab, infliximab and etanercept, among
others, could have benefits in the management of this condition by
blocking this factor (Alsantali 2011).
Other biological agents
Patients with AA present with hair follicle dystrophy and
acceleration of hair follicles into the catagen phase, due to an
over-expression of a variety of proinflammatory cytokines in
the hair follicle, along with a tissue upregulation of several γ-
chain cytokines (such as interleukin 2, 7, 15, and 21) and IFN-γ
elements, which are signalled through JAK1 and JAK2. The JAK-
inhibitors are able to block JAK signals, and suppress the T-cell-
mediated inflammatory responses, which promotes hair growth by
stimulating the activation and proliferation of hair follicle stem cells
and other related mechanisms (Schwartz 2017).
Treatments for alopecia areata: a network meta-analysis (Protocol)









Cochrane Database of Systematic Reviews
Topical immunotherapy (contact immunotherapy)
The mechanism of action of contact immunotherapy is not fully
understood. Some studies suggest that the induced allergic contact
dermatitis attracts CD4+ T away from the perifollicular region,
changing the milieu of immune cells surrounding hair follicles.
Other potential mechanisms include the non-specific stimulation
of T suppressor cells in the skin, the increase of local expression
of transforming growth factor beta, and the activation of myeloid
suppressor cells contributing to auto-reactive T cell silencing (Pratt
2017).
Hair growth stimulants
Minoxidil is a vasodilator that causes hypertrichosis (excessive hair
growth anywhere on the body) as a secondary eOect, and some
authors have proposed a role for it as a topical treatment for AA.
This eOect could be the result of vasodilation, which facilitates the
supply of oxygen and nutrients to the hair follicles, which in turn
induces formation of new vessels (Choi 2018). On the other hand,
it is important to mention that vascular endothelial growth factor,
produced by endothelial cells and expressed in hair follicles, is
associated with vasodilation processes and seems to be involved in
hair growth (Wu 2018).
Other therapies
There are other treatments for which mechanisms of action are
not fully understood. Laser therapy has been used in children with
patchy AA, with variable results. The most common wavelengths
used are 308 nanometer (nm) (excimer laser), 904 nm (diode laser),
and 1540 nm (Er:glass laser) (Al-Mutairi 2007; Waiz 2006; Yoo 2010).
Cryotherapy has also been used in patches of alopecia areata,
however its mechanism of action is not clear. It could be
related to the eOect produced by exposure for a short period
to liquid nitrogen, which increases blood flow and improves
microcirculation through reactive vasodilatation (Jun 2017).
Why it is important to do this review
In 2017, Cochrane Skin undertook a large-scale exercise with
stakeholders for prioritization of systematic reviews to be
developed in the next two years. Specifically, one of the target
conditions prioritized was AA, which is a common autoimmune
disease aOecting all types of people around the world, with reports
of cumulative life incidence up to 2% (Mirzoyev 2014). As mentioned
above, AA aOects the quality of life of patients and caregivers, and
interferes especially with their daily activities. In addition, AA is
an important cause of absence from both school and work, and
it generates consequences in the global economy and excess of
burden for the healthcare system.
In addition, it is important to highlight the contribution of Macbeth
and colleagues, who presented the top 10 research priorities for
AA in the UK, which include at least three issues related to the
objectives of this review, as follows (Macbeth 2017).
• Are immunosuppressant therapies better than placebo in the
treatment of AA?
• In AA, are biological therapies (including JAK inhibitors and anti-
cytokine therapies) more eOective than placebo in causing hair
regrowth?
• Do any treatments have a long-term therapeutic benefit in AA?
Cochrane Skin published a systematic review of AA in 2008
(Delamere 2008); however, new evidence about the eOectiveness
and safety of potential treatments has been published in the
last decade. The update of this systematic review is essential.
In addition, due to the numerous interventions proposed for
the management of AA, the methodology of a systematic review
with network meta-analysis will be an important tool to assess
the diOerent alternatives and to guide clinical practice through a
complete comparison of proposed treatments for AA.
Finally, this updated systematic review will identify the existing
gaps in the evidence related to the management of this condition,
and can be used to inform new lines of AA research.
O B J E C T I V E S
To assess the comparative eOectiveness and safety of interventions
used in the management of alopecia areata (AA), including patchy
alopecia (PA), alopecia totalis (AT) and alopecia universalis (AU).
To establish rankings of the available treatments for AA, based
on their eOectiveness and safety (primary outcomes), through a
network meta-analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs) that evaluate
eOectiveness and safety, or both. We will consider RCTs with parallel
groups, cluster-randomized trials, cross-over trials, experiments
with repeated measures on participants, multiple intervention
groups, half-head studies, and multiple body parts.
Types of participants
We will consider individuals who have been diagnosed by a medical
practitioner with AA, AT or AU, including both paediatric and adult
populations. We will only include studies in which there is a subset
of relevant participants if it is possible to obtain specific and
separate information. We will pose no restrictions on age, sex,
or ethnicity of the participants. This absence of restrictions may
threaten transitivity and introduce heterogeneity, as several of the
characteristics of the participants act as potential treatment eOect
and safety modifiers (see 'Assessment of transitivity in the network
meta-analysis', below). This issue will be addressed by performing
subgroup analyses and network meta-regression (see Subgroup
analysis and investigation of heterogeneity). Diagnosis of AA can
be achieved by clinical examination, trichoscopy/dermoscopy, or
biopsy. We will exclude trials with participants suOering from
androgenetic alopecia and cicatricial alopecia.
Types of interventions
Decision Set
Studies should include one or more of the following interventions,
delivered at any dose, duration, and follow-up time.
Immunosuppressant therapy
• Topical corticosteroids
• Topical calcineurin inhibitors
• Intralesional corticosteroids
Treatments for alopecia areata: a network meta-analysis (Protocol)
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Topical immunotherapy (contact immunotherapy)
• Dinitrochlorobenzene (DNCB)
• Diphencyprone (DPCP)











• Mesotherapy (zinc, selenium, biotin, platelet-rich plasma)
Interventions can be administered either as single therapy or in
combination.
Reference set
The comparators will be placebo, no treatment, vehicle only, or
another active compound.
Types of outcome measures
We consider for this section the recommendations of the consensus
of Olsen and colleagues to obtain objective outcome measures on
AA. We will use the Severity of Alopecia Tool (SALT), which evaluates
the percentage scalp involvement, in preference to other reported
measures (Olsen 2018).
Primary outcomes
1. The proportion of participants with clinically significant hair
regrowth, as rated by the participant or medical practitioner (where
both types of rating are available, we will use medical assessment).
We deem ≥ 75% regrowth of the aOected area to constitute
significant hair regrowth.
2. Incidence of serious adverse events: including mortality,
hospitalization, surgical intervention, temporary or permanent
sequelae, and serious infections. We will consider the number of
participants with at least one serious adverse event.
Secondary outcomes
1. Health-related quality of life, measured with validated
instruments such as the Alopecia Areata Quality of Life Index
(AA-QLI) (Fabbrocini 2013), Dermatology Life Quality Index (DLQI)
(Finlay 1994), and Skindex (versions 29 and 16) (Chren 2012).
2. The proportion of patients with long-term sustainability of hair
regrowth (greater than 26 weeks).
Studies which do not report outcomes of interest will not be
excluded. In this case, the outcomes will be described as presented
by the study authors. In case of studies with extremely vague
outcomes, or if the outcome is not clearly described but seems
most likely to map to one of our predefined outcomes, then we
will describe the outcome narratively and take into consideration
narrative information when interpreting the results of the meta-
analyses.
Timing of outcomes
Regarding time points and follow-up, Olsen and colleagues
recommend that at least a 12-week observation period should
be measured (Olsen 2018). Therefore, we will describe the results
obtained in the longest follow-up time reported by adequate
numbers of trials for meaningful and representative meta-analysis.
We will classify outcomes as short-term (between 12 and 26 weeks)
and long-term (greater than 26 weeks). In case of multiple time
points of measurements, we will use the result closest to 12 weeks
for short-term outcomes and closest to one year for long-term
outcomes. We will assess whether the time point assessment
reported is biologically reasonable, and we will also consider the
quantity and quality of data available for each time-point that
might be pooled in meta-analysis. We will take these considerations
into account when assessing the quality of the study. We will
perform analyses of studies with outcome data at similar time
points.
The duration of the treatment may threaten transitivity as it is
a potential safety modifier (see 'Assessment of transitivity in the
network meta-analysis', below). This issue will be addressed by
comparing adverse events at similar timings (long-term).
Search methods for identification of studies
We aim to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
The Cochrane Skin Information Specialist will search the following
databases for relevant trials, with no restriction by date.
Treatments for alopecia areata: a network meta-analysis (Protocol)
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• The Cochrane Skin Specialised Register
• The Cochrane Central Register of Controlled Trials (CENTRAL) in
the Cochrane Library
• MEDLINE via Ovid (from 1946 onwards)
• Embase via Ovid (from 1974 onwards)
The Information Specialist has devised a draS search strategy for
RCTs for MEDLINE (Ovid), which is displayed in Appendix 1. This will
be used as the basis for search strategies for the other databases
listed.
Trial registers
We (MGUR, DSC) will search the following trial registers using
the key words “alopecia areata” or “patchy alopecia areata” or
“alopecia universalis” or “alopecia areata universalis” or “alopecia
totalis” or “alopecia areata totalis”.
• ClinicalTrials.gov (www.clinicaltrials.gov)
• The World Health Organization International Clinical Trials
Registry Platform (ICTRP) (www.who.int/trialsearch)
Searching other resources
Searching reference lists
We will check the bibliographies of included studies and any
relevant systematic reviews identified for further references to
relevant trials, including the reference lists of the previous
Cochrane Review of AA (Delamere 2008).
Correspondence with trialists/experts/organizations
We will contact original authors for clarification and further data if
trial reports are unclear, specifically to obtain non-reported data or
missing results that are relevant for the estimation of the outcomes
of interest.
Adverse e!ects
We will not perform a separate search for adverse eOects of
interventions used for the treatment of AA. We will consider adverse
eOects described in included studies only.
Data collection and analysis
The results of the literature search will be collected in an EndNote
library, where duplicate studies will be removed. The file will then
be exported to Covidence for the screening process (Covidence
2019).
Selection of studies
Two review authors from a panel of four (MN, GSV, MGUR, DSC)
will independently select studies for eligibility. We will review titles
and abstracts of all identified studies to determine whether they
fulfil the inclusion criteria. We will assess the full texts of selected
studies to confirm their relevance for inclusion. We will be selecting
RCTs based on the comparison within the trials. We will resolve
any disagreements by consulting a third author (SVG). We will not
be blinded to the study authors’ names and institutions, journal
of publication, or study results at any stage of the review. We
will record the reasons for exclusion of potential studies in the
'Characteristics of excluded studies' tables.
Data extraction and management
Two review authors from a panel of four (SVG, MGUR, LGM, DSC) will
independently use The Skin Group's data extraction form, tailored
for this systematic review, to extract information on the description
of interventions, participants, outcome measures, methods, and
methodological quality. This data extraction form will be piloted
with a set of included trials.
Regarding outcomes, we will extract the number of participants
allocated to each intervention group and the proportion of patients
that reached more than 75% hair regrowth. We will extract the
proportion or incidence of participants in each group with at
least one serious adverse event (mortality, hospitalization, surgical
intervention, temporary or permanent sequelae, and serious
infections). We will extract from each trial the event rates and
descriptions of serious adverse eOects. We will also extract the
results related to our secondary outcomes: health-related quality
of life and incidence of disease relapse. We will extract means and
standard deviations per study arm if outcomes are reported as
continuous outcomes rather than binary outcomes.
We will resolve any disagreement by discussion with a third review
author (GSV). We will enter extracted data into Review Manager 5.4
(RevMan 2020) or RevMan Web (RevMan Web 2019), or both; and we
will use Stata Statistical SoSware (release 15) for further analyses
(Higgins 2019a; Stata 2017).
Assessment of risk of bias in included studies
We will use version 2 of the Cochrane 'Risk of bias' tool (RoB2) for
RCTs (Sterne 2019) to evaluate the risk of bias of each included trial.
This will be done independently by two review authors from a panel
of four (IAR, GSV, MN and SVG), following the recommendations
in Chapter 8 of the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2019b). Disagreements will be resolved by
discussion with a third author (JZ). The interest of our review will be
assessing the eOect of assignment to the interventions at baseline.
As the Handbook recommends, we will evaluate each outcome
using the RoB2 tool. The domains of this tool for RCTs include the
following.
• Bias arising from the randomisation process
• Bias due to deviations from intended interventions
• Bias due to missing outcome data
• Bias in measurement of the outcome
• Bias in selection of the reported result
Each domain has a group of signalling questions to retrieve relevant
information for an assessment of risk of bias. The options are: yes,
probably yes, probably no, no, no information. According to the
answers, the 'Risk of bias' judgement for each domain would be
either: low risk of bias, some concerns, or high risk of bias.
The overall judgement about risk of bias depends on the result of
each domain, as presented below.
• Low risk of bias: the study is judged to be at low risk of bias for
all domains for this result.
• Some concerns: the study is judged to raise some concerns in at
least one domain for this result, but not to be at high risk of bias
for any domain.
Treatments for alopecia areata: a network meta-analysis (Protocol)
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• High risk of bias: the study is judged to be at high risk of bias in
at least one domain for this result, or the study is judged to have
some concerns for multiple domains in a way that substantially
lowers confidence in the result.
The 'Risk of bias' assessments will inform our GRADE evaluations
of the certainty of evidence for those outcomes presented in the
'Summary of findings' tables, and will also be used to inform the
sensitivity analysis for studies at low risk of bias for the primary
outcomes (see Sensitivity analysis).
For each bias judgement we will use the Excel template, which
is available at https://www.riskofbias.info/welcome/rob-2-0-tool/
current-version-of-rob-2. Each file will be stored on a scientific data
website, available to readers.
Risk of bias in cluster-randomized controlled trials
In case of cluster-RCTs, we will start with RoB2 as it is, but we
will also include the domain: 'bias derived from the moment of
identification and recruitment of participants', using the signalling
questions from Domain 1b. We will also follow the description
included in Section 23.1.2 in the Cochrane Handbook and in Table
23.1, to assess bias in this type of study (Higgins 2019c).
Risk of bias in cross-over randomized controlled trials
For this type of study we will start with RoB2 as it is, and for Domain
2 ('bias due to deviations from the intended interventions') and
Domain 3 ('bias due to missing outcome data'), we will use the
respective signalling questions from the RoB2 tool guidance for
cross-over RCTs (Higgins 2019c).
Measures of treatment e9ect
Relative treatment e!ects
For each dichotomous outcome, we will estimate the relative
treatment eOects using risk ratios (RRs), with 95% confidence
intervals (CIs). In case of a continuous outcome (i.e. quality-of-
life scores), we will analyze data using mean diOerences (MDs)
or standardized mean diOerences (SMDs), with their respective
95% CI. We will make the SMD easier to understand by back-
transforming to a known scale.
Relative treatment ranking
We will present treatment hierarchies using rankograms,
cumulative probability plots and clustered ranking graphs
(Chaimani 2013). We will use SUCRA and mean rank, along with
corresponding CIs, to indicate the uncertainty of rankings (Salanti
2011). We will not determine rankings using probabilities. If we
identify too much uncertainty, we will not rank treatments.
Unit of analysis issues
Following the guidance from the Handbook (Higgins 2019d), we
will consider the potential impact of diOerent designs on the
analysis, including special considerations for cluster-randomized
trials, cross-over trials, experiments with repeated measures on
participants, multiple intervention groups, and multiple body
parts.
Cluster-randomized trials
In case of cluster-randomized trials, we will perform the analysis at
the same level as the allocation, using a summary measurement
from each cluster, following the recommendations in the Handbook
(Higgins 2019c). If a cluster-randomized trial provides results
unadjusted for its cluster design, we will reduce the eOective
sample size accounting for the design eOect using the reported
intracluster correlation coeOicient (ICC), or in case the study does
not report the ICC, we will use an ICC obtained from a similar
trial from the literature. We will assess the eOect of the unit of
randomization in a sensitivity analysis.
Cross-over trials
Clinical research in dermatology oSen uses cross-over designs,
by the assignment of patients to a sequence of interventions (AB
or BA). We will check the appropriateness of a cross-over design
(i.e. check for the presence of a carry-over eOect of intervention,
or period eOect or irreversibility of outcome). In accordance with
the guidance in the Handbook (Higgins 2019c), we will follow the
conservative option of including data from the first trial period only
if the cross-over design is deemed inappropriate.
Repeated measures on participants
Where there are repeated measures of the outcome of interest
within a study (for instance, at three, six, nine, and 12 months),
we will analyze the longest follow-up time reported, and classify
it as short-term (less than 12 weeks) or long-term (greater than 12
weeks) (see 'Timing of outcomes', above). During the analysis we
will group trials that report similar timings, to make comparisons
between studies.
Multiple intervention groups
If we include trials which have relevant comparisons between
more than two groups in a pair-wise meta-analysis, we will split
participants in the control group into two or more groups; this is to
avoid double-counting participants. In the network meta-analysis,
multi-arm trials are split into separate nodes of the network, so
double-counting of patients is not a concern as long as within-
trial correlation is adequately considered in the analysis (Franchini
2012).
Multiple body parts
In the context of AA, diOerent parts of the body could be randomized
to diOerent interventions (i.e. split-head designs). If outcomes are
evaluated at the level of body parts despite being randomized at
participant level, and the data were not correctly analyzed, we will
assess whether it is possible to approximate the correct analysis
following guidance provided in the Handbook (Higgins 2019c). If
studies do not provide suOicient information to approximate the
correct analysis, we will exclude the data from the analysis.
Dealing with missing data
In studies with missing data, we will contact trial authors or
sponsors and we will make requests for missing data. We will create
a table with information about the authors contacted and the
information requested and received.
Assessment of heterogeneity
We will explore the variability between studies, analyzing the
diOerent sources of clinical and methodological heterogeneity.
We will describe trial population characteristics across included
trials and will assess the presence of clinical or methodological
heterogeneity by comparing their characteristics. For our pair-
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wise analyses, we will use the statistical test included in Review
Manager 5.4 or RevMan Web (RevMan 2020; RevMan Web 2019).
The Chi2 test performs an evaluation of the chance to explain the
variability, with heterogeneity occurring if a P value is less than
0.1. In addition, we will use the I2 to quantify the heterogeneity,
through a description of the variability in eOect estimates that is
due to heterogeneity. We will explore sources of heterogeneity by
performing subgroup analysis and meta-regressions (see Subgroup
analysis and investigation of heterogeneity).
Assessment of transitivity in the network meta-analysis
The transitivity assumption concerns the validity of making indirect
comparisons. This assumption relies on whether the eOect of an
intervention estimated using indirect comparisons is similar to the
eOect estimated using a direct comparison. We will tabulate direct,
indirect and mixed evidence for each comparison to facilitate the
assessment of transitivity. We will explore trial characteristics to
identify between-study diOerences in the distribution of potential
treatment eOect modifiers across each of the comparisons in the
network (Jansen 2013). We will consider the following clinical and
methodological factors to be potential treatment eOect modifiers:
for eOicacy outcomes, we will consider age, early onset of the
disease, clinical form, severity of the disease, extension of hair
loss, and coexisting nail changes. Regarding safety, we will consider
age, treatment duration, comorbidities and poly-medication (see
Subgroup analysis and investigation of heterogeneity).
Assessment of statistical incoherence in the network meta-
analysis
If there are diOerences across studies that involve diOerent
interventions of the network, the transitivity assumption may not
be met and it may generate statistical incoherence (Higgins 2012).
We will check for local incoherence using the node-splitting
approach, which requires a closed loop with at least three
treatments compared to each other (Dias 2010). This technique
will be applied to all comparisons in the network to estimate the
diOerence between direct and indirect comparisons, jointly with
95% CIs. To determine global consistency of the network, we will
use the “design by treatment” interaction model (Higgins 2012),
using multivariate meta-analysis. The model will estimate a global
Chi2 test for network incoherence. We will consider as incoherence
a P value of less than 0.05. We will explore the following variables
as a possible source of incoherence: severity of disease, adult
or paediatric population, risk of bias, and duration of follow-up,
among others.
Assessment of reporting biases
We will use funnel plots for the primary outcomes to provide a
visual assessment of reporting bias, if at least 10 trials are available
(Higgins 2019a; Sterne 2011). We will assess reporting bias for
pairwise comparisons using contour-enhanced funnel plots. We
will also use two tests to assess asymmetry in the corresponding
funnel plots: the regression asymmetry test (Egger 1997) and the
adjusted rank correlation test (Begg 1994). Assessment of reporting
bias will be performed in pairwise meta-analysis. We will use
comparison-adjusted funnel plots to assess reporting biases and
small-study eOects for the network meta-analysis (Chaimani 2012;
Chaimani 2013).
Data synthesis
Methods for direct treatment comparisons
We will perform pairwise meta-analysis for each direct comparison,
using the random-eOects model (DerSimonian and Laird method).
This allows us to summarize the findings while accounting for
between-study heterogeneity. If the available number of studies
is insuOicient to estimate between-study variance (e.g. only two
studies), we will perform a fixed-eOect meta-analysis instead.
As treatment eOect measures, dichotomous outcomes will be
reported as RRs with 95% CIs. Where results are estimated for
individual studies with low numbers of events (less than 10 in total),
or where the total sample size is less than 30 participants and a
RR is used, we will report the proportion of events in each group
together with a P value from a Fisher’s Exact test. Where outcomes
are expressed as continuous data (i.e. quality-of-life scores), the
analysis will use MD, or SMD if the same outcome is measured with
diOerent measurement tools, including 95% CIs (Higgins 2019a). We
will use the soSware Review Manager 5.4 or RevMan Web (RevMan
2020; RevMan Web 2019).
Methods for network meta-analysis
Firstly, we will build a graphical description of the evidence network
to assess its geometry (Chaimani 2013). We plan to represent
graphically the network structure with nodes and edges, including
a short-term eOicacy network, a long-term eOicacy network, and
a long-term security network, with all the individual treatments
that meet the requisites. Secondly, we will assess whether the
transitivity assumption holds comparing populations and settings
among studies. Finally, we will assess consistency formally in the
network using methods described above, then we will perform
the network meta-analysis within a frequentist framework using
multivariate meta-analysis. We will use random-eOects models to
estimate the relative treatment eOects using RRs and SMDs, with
95% CIs for each intervention compared to the anchor treatment.
We will estimate rankings of the relative eOect of all interventions
on AA and on safety, using the probability to be the best treatment
and the surface under the cumulative ranking curve (SUCRA)
(Chaimani 2013; Salanti 2011; Shim 2017). The analyses will be
performed using Stata Statistical SoSware, release 15 (Stata 2017),
using the 'network' suite of commands designed for this purpose
(White 2015). If the assumptions that preserve the validity of
the NMA are not met, only direct comparisons and a narrative
description of the findings will be made.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analyses and network meta-regression
if we identify a suOicient number of available studies, especially
for the factors that could explain the diOerences between the
treatments. The subgroup analysis will be performed for the
pairwise meta-analysis and the network meta-analysis. Subgroups
of main interest will be:
• age group (less than 12 years versus 12 years or more)
• the extent of hair loss (less than 75% versus 75% or more)
• the three types of alopecia according to the aOected area: a)
patchy alopecia (PA); b) alopecia totalis (AT); and c) alopecia
universalis (AU).
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We will also investigate other clinical or methodological factors
identified during the review process that may threaten transitivity,
as sources of incoherence or heterogeneity.
To compare the estimations of the subgroups, we will add the
subgroup factor into the random-eOects model. To test its statistical
significance, we will use a P value of less than 0.05 as a threshold to
consider a significant diOerence.
Sensitivity analysis
We will perform a sensitivity analysis, using the risk of bias as a
variable to explore the robustness of the findings. We will verify the
behaviour of our estimators, including and excluding studies with
a high risk of bias overall (see Assessment of risk of bias in included
studies).
Summary of findings and assessment of the certainty of the
evidence
We will create 'Summary of findings' tables for the primary
outcomes (see Primary outcomes). Each treatment will be
compared to placebo (reference) and ranked in order of
eOectiveness and safety in the 'Summary of findings' tables. We
will use the GRADE approach to assess the certainty of evidence for
each outcome listed above for our main comparisons (Schünemann
2013). In the 'Summary of findings' tables we will include: PICO
information, the network meta-analysis graphic, data presentation,
certainty of evidence, ranking of treatments, and interpretation of
findings. The assessment of the certainty of evidence is based on
a methodological framework which considers six domains: within-
study bias, reporting bias, indirectness, imprecision, heterogeneity,
and incoherence. To perform this assessment we will use the
CINeMA approach (Salanti 2014), and the CINeMA web application
(Nikolakopoulou 2019).
Two review authors from a panel of four (GSV, IAR, MN, SVG) will
independently appraise the certainty of evidence. Disagreements
between authors will be resolved through discussion or by
consultation with a third review author from a panel of three (DSC,
MGUR, JZ), where necessary.
We will use the approach proposed by Yepes-Nuñez and
Schünemann (Yepes-Nuñez 2018) to create our 'Summary of
findings' tables and undertake our GRADE assessments (Appendix
2).
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Term Definition
Adjuvant therapy Additional treatment given to the primary or initial therapy to maximize its effectiveness
Alopecia areata (AA) A common, inflammatory, nonscarring type of hair loss, characterized by small patches of baldness
on the scalp or around the body, as well as periods of relapse or remission
Alopecia totalis (AT) Alopecia that affects all scalp hairs
Alopecia universalis (AU) Alopecia that involves all scalp and body hairs
Antigen A substance that invokes an immune response
Biologic agents Compounds produced by living cells using recombinant DNA technology
Blistering Circumscribed elevations of the epidermis, fluid-filled due to separation of two layers of tissue and
the leakage of plasma into the space
Catagen phase A phase of 2 to 3 weeks of duration when growth stops and the follicle shrinks
Chemokines Molecular messengers through which epithelial cells communicate with key cells in the immune
system
Coudability hairs Normal-looking hairs tapered at the proximal end (i.e. the hair root)
Cryotherapy Tissue destruction techniques produced by the application of cold on the skin
Cutaneous atrophy Skin thinning
Dendritic Cells The major antigen-presenting cells; these cells capture, process, and present antigens to T cells in
order to induce adaptive immunity or tolerance to self-antigens
Downregulation The process by which a cell reduces or suppresses the quantity of a cellular component
Exclamation mark hairs Short hairs, 3 mm long, with irregular thickening and terminal dilation
Exudate A fluid rich in protein and cellular elements that results from a continuous inflammatory response
First choice Treatment regimen accepted for the primary or initial therapy
Hair follicle A small cavity in the epidermis, from which a hair develops
Hepatotoxicity The result of chemical-driven liver damage
Immune privilege Multiple mechanisms that prevent autologous attack by immune cells in certain locations, such as
the hair follicle
Immunosuppressant therapy Treatment that reduces the activity of the body's immune system
Incidence The rate of new (or newly diagnosed) cases of the disease
Interleukins Potent cytokines (proteins) produced by some leukocytes (white blood cells), which function as
mediators of cell growth, inflammation, immunity, differentiation and repair
Keratins A fibrous protein that occurs in the outer layer of the skin and in the hair and nails
Table 1.   Glossary of terms 
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Langerhans cells Dendritic cells (which regulate the cellular immune response) present in all layers of the epidermis
as a dense network of immune system indicators
Laser therapy A medical treatment where a light source is used; radiant energy in the form of photons and waves
is capable of producing special biological effects
Lymphocytes Leukocyte whose main function is the regulation of the adaptive immune response
Macrophages Cells derived from monocytes residing in various tissues; their function is to present the antigens
to the lymphocytes to initiate the immune response and destroy, by phagocytosis (the process by
which a cell binds to and engulfs something), the antigens and the cells that transport them
Monocytes Circulating blood cells whose main function is phagocytosis
Patchy alopecia (PA) Round or oval patches of alopecia located on the head or in different regions of the body
Phototherapy Therapeutic use of ultraviolet radiation
Prevalence Proportion of individuals from a population that present with the event in a given period of time
Pruritus Feeling that leads to scratching
Psoralens Photoactive medication
PUVA Administration of a psoralen and subsequent exposure to ultraviolet radiation A
Regrowth Reappearance or return
T cells Cells that are programmed to recognize, respond to, and remember antigens
Tumour Necrosis Factor alpha
(TNF alpha)
An inflammatory cytokine produced by macrophages/monocytes responsible for different sig-
nalling events within cells, leading to necrosis (cell death) or apoptosis (programmed cell death)
Upregulation The process by which a cell increases the quantity of a cellular component
Vehicle A treatment without active ingredients
Table 1.   Glossary of terms  (Continued)
 
 
A P P E N D I C E S
Appendix 1. MEDLINE (Ovid) search strategy
1. exp Alopecia Areata/
2. nonscarring hair loss$.ti,ab.






9. ((spot$ or patch$) and baldness).ti,ab.
10. autoimmune hair loss$.ti,ab.
11. (alopecia adj3 (spot$ or nonscarring or non-scarring or areat$ or barbae or patch$ or semiuniversalis or autoimmune or totalis or
circumscripta or liminaris or universalis or circumscribed or diOuse or Jonston$ or marginal or snake-shaped)).ti,ab.
12. or/1-11
13. randomized controlled trial.pt.
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14. controlled clinical trial.pt.
15. randomized.ab.
16. placebo.ab.
17. clinical trials as topic.sh.
18. randomly.ab.
19. trial.ti.
20. 13 or 14 or 15 or 16 or 17 or 18 or 19
21. exp animals/ not humans.sh.
22. 20 not 21
23. 12 and 22
Appendix 2. NMA-SoF Table
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Estimates of the effects, confidence intervals and certainty of the evidence: treatments in patients with alopecia areata
 
























of studies. Number of
participants
RR (CI 95%)       Very low, low, mod-
erate, high
     
                 
                 
 NMA-SoF table definitions
a Estimator of effect, with confidence interval in frequentist approach or credible interval in Bayesian analysis.
b Anticipated absolute effect compares two risks by calculating the difference between the risks of the intervention group with the risks of the con-
trol group.
c Surface under the cumulative ranking (SUCRA), with confidence interval in frequentist approach or credible interval in Bayesian analysis. Proba-
bility to be the best, the second, the third, and so on until the least effective treatment.
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